J

Johnson & Johnson

Makes prescription drugs and medical devices

Associate Medical Science Liaison Manager - Hematology

Full-TimeUpdated on 10/15/2026
No salary listed
Mid
Master's, PhD, MD
Tianjin, China
In Person
Biology & Biotech

About the job

Requirements
  • A master's degree in medical science or pharmacology.
  • A medical doctor or PhD qualification is preferred.
  • Three or more years of Medical Science Liaison experience is preferred.
  • Deep understanding of therapeutic areas and the broader external market, including competitors and healthcare, regulatory, and reimbursement environments.
  • Proficiency in differentiating the organization and interpreting and analyzing scientific information to inform business strategy.
  • Ability to influence and communicate effectively to establish and maintain partnerships with internal and external customers.
  • Ability to use insights to identify, evaluate, prioritize, and communicate strategic choices that improve investment decisions and gain support.
  • Ability to identify and prioritize evidence gaps, anticipate future evidence needs, and address them through evidence generation aligned with therapeutic area strategy.
  • Ability to work independently with minimal supervision, meet tight deadlines, and maintain a positive attitude.
  • Analytical skills to identify gaps and develop solutions.
  • Good command of English, including fluent writing, speaking, and listening.
  • Ability to complete required onboarding and compliance training and pass associated assessments during the probationary period.
Responsibilities
  • Identify, develop, and engage key opinion leaders at the regional level.
  • Communicate and interpret medical and scientific data and information to key opinion leaders proactively and reactively.
  • Champion the medical benefits of products through scientific interactions with key opinion leaders and contribute to innovative therapeutic approaches for patients.
  • Use customer engagement strategies, skills, and technology to uncover actionable insights on treatment strategies, needs, and priorities relevant to customers and Janssen.
  • Build a scientific information resource network proactively.
  • Identify and disseminate emerging scientific and medical information from multiple sources to keep customers and business partners informed of significant advancements.
  • Respond to customer scientific queries about approved products and products or indications in development, using medical information documents such as literature, safety records, and scientific FAQs.
  • Organize and moderate advisory boards in cooperation with therapeutic area groups.
  • Provide medical and product training and scientific support to sales representatives in coordination with the Marketing team, as appropriate.
  • Collect insights from external customers and provide timely feedback to shape brand and medical strategy.
  • Organize local or regional medical education activities, including program development and speaker selection and support, in collaboration with Medical Education and Medical Affairs, as appropriate.
  • Support national and regional medical education events, including material development and speaker selection and support, in collaboration with Medical Education and Medical Affairs.
  • Support local and regional Medical Affairs programs and activities.
  • Ensure program implementation complies with requirements.
  • Identify and prioritize evidence gaps, anticipate future evidence needs, and address them through evidence generation aligned with therapeutic area strategy.
  • Apply strategic and technical knowledge of evidence generation from research concept formulation through publication to generate evidence in a timely manner.
  • Complete required domestic and international travel.
Desired Qualifications
  • Analytics dashboards.
  • Clinical experience.
  • Coaching.
  • Communication.
  • Competitive landscape analysis.
  • Critical thinking.
  • Cross-functional collaboration.
  • Customer centricity.
  • Data gathering and analysis.
  • Digital culture and digital literacy.
  • Interpersonal influence.
  • Medical Affairs and medical communications.
  • Medical compliance.
  • Problem solving.
  • Research and development.
  • Stakeholder engagement.
  • Strategic thinking.
  • Technical credibility.
  • Technological savvy.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.

Yahoo Finance
Oct 13th, 2026
Memory stocks slide on Chinese chip breakthrough as UnitedHealth and Goldman beat estimates

US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.

CNBC
Oct 13th, 2026
J&J beats estimates and lifts forecast to $101.2B, but Middle East conflict hurts device sales

Johnson & Johnson (J&J) beat earnings estimates, but the Middle East conflict hurt its medical-device sales in the region. Chief financial officer Joe Wolk said Gulf states such as Kuwait, the UAE, and Saudi Arabia are shifting budgets towards defence. The conflict has not yet raised J&J's costs. Tremfya sales rose 68% to $2.4 billion, beating estimates of about $2.19 billion. Stelara sales, which face generic competition, fell 54% to $716 million, above expectations of $591 million. Darzalex sales rose about 16% to $4.24 billion, short of the $4.4 billion expected. J&J raised its full-year sales forecast to about $101.2 billion at the midpoint, from $101.1 billion. Its adjusted earnings midpoint rose to $11.10 per share from $11.04. Shares closed at $263.73 on Monday, up 27% this year.

Yahoo Finance
Oct 11th, 2026
J&J reports Q3 results on October 13 as $622.84B giant eyes $2.82 EPS

Johnson & Johnson will report third-quarter results on October 13, before the market opens. Analysts expect earnings per share (EPS) to edge up to $2.82, and the company has beaten EPS estimates in each of the past four quarters. The healthcare group, valued at $622.84 billion, has seen its stock rise 36.8% over 52 weeks. Shares are down 8.1% from their September 2 high of $281.07. In the second quarter, sales rose 6.6% to $25.31 billion, and adjusted EPS climbed 4.7% to $2.90. J&J raised its 2026 adjusted EPS estimate from $11.55 to $11.68. Of 25 analysts, 14 rate the stock "Strong Buy." The consensus price target of $282.60 implies 9.3% upside.

Yahoo Finance
Sep 18th, 2026
J&J stock trades at 28x earnings, but STELARA biosimilar hit distorts valuation

Johnson & Johnson stock has surged 57% over the past year, outpacing the S&P 500's 17% return. Trading at approximately $270 per share, the stock appears expensive at 28.3 times trailing earnings. However, those trailing figures include STELARA, which lost market share to biosimilar competition and reduced operational sales growth by 460 basis points in Q2 2026. Excluding STELARA, the company achieved double-digit growth. The forward outlook looks more attractive, with the stock trading at 24.1 times fiscal 2026 earnings and 20.9 times 2027 estimates. Johnson & Johnson's portfolio includes 28 products generating over $1 billion annually each, with trailing twelve-month revenue near $98 billion. Meanwhile, TREMFYA grew 71% in Q2 2026, becoming the fastest-growing advanced therapy in Crohn's disease and ulcerative colitis. Operating margins improved to 26.8% from a three-year average of 25.7%, supporting expectations for continued margin expansion.